Analyst Reco. Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
7.35 ^USD	-0.68%		-12.60%	-25.46%

Apr. 18	Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	MT
Apr. 16	Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	Apr. 18	MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	Feb. 28	MT
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	Jan. 26	MT
JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating	Nov. 13	MT
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating	Nov. 10	MT
KeyBanc Adjusts Price Target on Recursion Pharmaceuticals to $15 From $12, Maintains Overweight Rating	23-07-13	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $35 From $33, Maintains Buy Rating	23-07-13	MT
Morgan Stanley Lifts Price Target on Recursion Pharmaceuticals to $11 From $8 Amid NVIDIA Partnership, Keeps Equalweight Rating	23-07-13	MT
Keybanc Adjusts Price Target on Recursion Pharmaceuticals to $12 From $20, Keeps Overweight Rating	23-05-09	MT
Needham Starts Recursion Pharmaceuticals at Buy With $17 Price Target	23-03-16	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating	23-02-02	MT
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating	23-01-23	MT
Berenberg Discover AI Seminar	22-11-28	FA
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	22-11-16	MT
Goldman Sachs Adjusts Price Target on Recursion Pharmaceuticals to $9 From $8, Maintains Neutral Rating	22-11-09	MT
KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target	22-09-16	MT
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum	22-08-18	PR
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating	22-08-11	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains Buy Rating	22-06-22	MT
Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rating Kept	22-05-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Analyst Reco.

Filters